Nuvation Bio Class A (NUVB) closed at $4.69 on November 3, 2026, up 2.2% from the previous close, on volume of 4,791,404 shares (30-day average 5,085,999).
Data as of November 3, 2026.
PRNewswire (Mon, 2-Nov 8:00 AM ET)
PRNewswire (Thu, 29-Oct 8:00 AM ET)
PRNewswire (Wed, 21-Oct 4:06 PM ET)
NUVB highlights nearly 50-month median response as FDA updates IBTROZI label ahead of schedule
Market Chameleon (Fri, 18-Sep 7:41 AM ET)
NUVB Wins FDA Label Update for IBTROZI Highlighting 49.70-Month Median Response Duration
Market Chameleon (Thu, 17-Sep 3:54 AM ET)
PRNewswire (Thu, 17-Sep 7:30 AM ET)
PRNewswire (Tue, 15-Sep 8:00 AM ET)
Nuvation Bio to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 2-Sep 4:06 PM ET)
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
PRNewswire (Thu, 20-Aug 8:00 AM ET)
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
PRNewswire (Thu, 6-Aug 7:31 AM ET)
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Nuvation Bio Class A trades on the NYSE stock market under the symbol NUVB.
As of November 3, 2026, NUVB stock price climbed to $4.69 with 4,791,404 million shares trading.
NUVB has a beta of 1.35, meaning it tends to be more sensitive to market movements. NUVB has a correlation of 0.05 to the broad based SPY ETF.
NUVB has a market cap of $1.65 billion. This is considered a Small Cap stock.
Last quarter Nuvation Bio Class A reported $32 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $4 million and missed earnings estimates by -$.05.
In the last 3 years, NUVB traded as high as $9.75 and as low as $1.21.
The top ETF exchange traded funds that NUVB belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
NUVB has underperformed the market in the last year with a return of -10.2%, while the SPY ETF gained +11.7%. In the last 3 month period, NUVB fell short of the market, returning -25.9%, while SPY returned +1.2%. However, in the most recent 2 weeks NUVB has outperformed the stock market by returning +4.7%, while SPY returned -1.6%.
NUVB support price is $4.43 and resistance is $4.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVB shares will trade within this expected range on the day.
